Thomas James Lynch MD

Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology); Director, Yale Cancer Center; Physician-in-Chief, Smilow Cancer Hospital at Yale-New Haven

Departments & Organizations

Cancer Center, Yale: Thoracic Oncology Program | Developmental Therapeutics

Internal Medicine: Medical Oncology


Research Interests

Lung cancer; EGFR; Targeted therapy; Personalized medicine  more...


Education

  • B.S., Yale University, 1982
  • M.D., Yale University School of Medicine, 1986

Selected Publications

  • Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ann Oncol. 2013 Jan;24(1):75-83.
  • Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. J Clin Oncol. 2012 Jun 10;30(17):2046-54.
  • Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer. Politi K, Lynch TJ. Clin Cancer Res. 2012 Mar 15;18(6):1490-2.

more...

collapsible-single-column-one-thumbnailphotobooksupi=13129751/WCF/News.svc/

Latest News

3
more...

Edit Profile